Search

Displaying results 4771 - 4780 of 10000 in total
  1. Drug

    CHF5633

    go.drugbank.com/drugs/DB18696
    Investigational

    CHF5633 is a fully synthetic pulmonary surfactant preparation comprising DPPC (dipalmitoylphosphatidylcholine), POPG Na (palmitoyl‐oleoyl‐phosphatidylglycerol sodium), a synthetic SP-C analogue, and a

    Synonyms: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
  2. Drug

    GI-4000

    go.drugbank.com/drugs/DB05698
    Investigational

    A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.

  3. Drug

    VS-5584

    go.drugbank.com/drugs/DB12986
    Investigational

    VS-5584 has been used in trials studying the treatment of Lymphoma, Metastatic Cancer, and Non Hematologic Cancers.

  4. Drug

    Dopastatin

    go.drugbank.com/drugs/DB16144
    Investigational

    Dopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).

  5. Drug

    Delanzomib

    go.drugbank.com/drugs/DB11956
    Investigational

    Delanzomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, and Lymphoma, Non-Hodgkin.

  6. Drug

    BMS-275183

    go.drugbank.com/drugs/DB12144
    Investigational

    BMS-275183 has been used in trials studying the treatment of Tumors and Non-small Cell Lung Cancer.

  7. Drug

    RH-1

    go.drugbank.com/drugs/DB04090
    Investigational

    RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.

  8. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin. … APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.

  9. Drug

    Naveglitazar

    go.drugbank.com/drugs/DB12662
    Investigational

    Naveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.

  10. Drug

    Bevurogant

    go.drugbank.com/drugs/DB21507
    Experimental

    Bevurogant has a monoisotopic molecular weight of 532.2 Da. … The usage of the INN stem '-rogant' in the name indicates that Bevurogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist.